Engineered Cancer-Fighting Cells Show Promise in Trials

Researchers at MIT and Stanford University have developed a new method to stimulate the immune system to target tumor cells. This innovative strategy involves disabling sugar-based immune brakes on cancer cells, which could potentially expand the benefits of immunotherapy to a broader range of patients.

Recent studies have highlighted the effectiveness of engineered cancer-fighting cells in treating multiple myeloma, marking a significant advancement in cancer therapy.